

# Addressing R&D Challenges with RightFind Navigate

## Are R&D teams missing vital information?

Successful preclinical research often requires making connections that haven't been made before — and then demonstrating to internal stakeholders that findings are valid.

Missing something at the preclinical stage can range from being embarrassing to costing a company millions of dollars. Scientists need to stay on top of the latest understanding of indications and disease states in order to discover new ways to help patients and maintain a proprietary edge over the competition.

Teams need reliable, accurate data and evidence to create and support drug and device programs, to share with internal governance meetings, to inform investment decisions, and to ultimately meet regulatory requirements.

## Why is content discovery such a challenge?

38% of survey respondents in preclinical, translational research, or bioinformatics indicated “searching for and identifying relevant content” is their number one content challenge.<sup>1</sup>



The ever-increasing rate of publications, data, and patents is growing the likelihood of missing vital information.



Semantics of naming in biomedical data is complex and handled in different ways by different data sources.




It takes a significant amount of time to create multiple queries in different tools in order to search the necessary public, licensed, and proprietary sources of information.

<sup>1</sup> Imbue Partners, 2023 survey of 235 employees at life science companies

## RightFind Navigate can help.

RightFind Navigate uses an open integration framework that brings together licensed third-party data sources with internal proprietary information and publicly available resources.

Sample data sources include: ChemRxiv, BioRxiv, medRxiv, ChEMBL Compounds, Europe PMC, FDA@Drugs, NIH Clinical Trials, NIH RePORTER, PubChem, PubMed, and over 40 additional 3rd party licensed data sources.



## RightFind Navigate features for the R&D Pipeline:



Multiple types of content in one place means less interfaces to learn



Semantic search provides confidence in coverage to reduce the likelihood that critical content falls between the gaps



Alerts offer continuous monitoring of new and changing information relevant to your program



An analytics panel enables the ability to explore data in more depth



Keep up to date on the latest information in your area with personalized content recommendations

## How does scientific content in RightFind Navigate help R&D teams like early phase researchers, translational scientists, R&D IT, and data scientists?

Access to scientific literature, clinical trial registries, patents, news, and more, can help R&D teams:

- Discover the right content to find new ideas for drug programs
- Stay up-to-date on current disease state and competitor landscape
- Find and test new ideas, map pathways to therapeutic design, and move the best targets through the pipeline to the clinic
- Understand the emerging disease landscape, specifically which indications are the focus of current literature trends
- Stay current across rapidly moving drug target research in a complex therapy area
- Contextualize the competitor clinical trial landscape in competing drug programs, and how they are diagnosing disease, selecting patients, and measuring drug efficacy
- Comprehend the relevance of the preclinical animal models used and how to translate those results to a human and clinical setting where possible
- Understand the program's Target Product Profile (TPP) and how success can be both measured and delivered
- Enable contextual discovery of relationships between disparate data sets that may otherwise be missed or difficult to identify with data from a variety of sources

## RightFind Navigate is designed to help answer research questions across the enterprise:

EARLY DRUG DISCOVERY SCIENTISTS	TRANSLATIONAL SCIENTISTS	CLINICAL RESEARCHERS	PUBLICATIONS TEAMS/ MEDICAL AFFAIRS
<ul style="list-style-type: none"> <li>What topics in the literature are trending?</li> <li>Should my company pursue a new target?</li> <li>What are the genes that could be implicated in disease causality and should be considered as potential drug targets?</li> </ul>	<ul style="list-style-type: none"> <li>How translational are animal models to human disease?</li> <li>What are the potential human biomarkers for a disease?</li> <li>Are there any studies on the genetic diversity of patients with rheumatoid arthritis?</li> </ul>	<ul style="list-style-type: none"> <li>What is the current clinical trial landscape?</li> <li>What is the current thinking on patient stratification in my therapeutic area?</li> </ul>	<ul style="list-style-type: none"> <li>Are there any newly published articles that mention an adverse event or MOA for one of our products?</li> <li>What published articles have some direct or peripheral impact on the treatment landscape for one of our products?</li> </ul>

“A researcher can have more confidence that everything that can be found has been found, and can switch from finding evidence, to understanding it and building out what a possible new drug program looks like. RightFind Navigate helps save time and frustration and allows researchers to get on with drug program building with confidence, and helps maximize company ROI for proprietary data provision to impact exactly where it is needed.”

**Bryn Williams-Jones, COO, Connected Discovery**

### About CCC

A pioneer in voluntary collective licensing, CCC advances copyright, accelerates knowledge, and powers innovation. With expertise in copyright, data quality, data analytics, and FAIR data implementations, CCC and its subsidiary RightsDirect collaborate with stakeholders on innovative solutions to harness the power of data and AI.

### Learn more

Contact us to schedule a RightFind Navigate demo.

- U.S. Organizations: [copyright.com/navigate](https://copyright.com/navigate) | [solutions@copyright.com](mailto:solutions@copyright.com)
- Outside U.S. Organizations: [rightsdirect.com/navigate](https://rightsdirect.com/navigate) | [solutions@rightsdirect.com](mailto:solutions@rightsdirect.com)